Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report

@article{Vogelmeier2017GlobalSF,
  title={Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report},
  author={Claus F. Vogelmeier and Gerard J. Criner and Fernando J. Martinez and Antonio Anzueto and Peter John Barnes and Jean Bourbeau and Bartolom{\'e} R. Celli and Rongchang Chen and Marc Decramer and Leonardo M. Fabbri and Peter A. Frith and David M. G. Halpin and Maria Victorina Lopez Varela and Masaharu Nishimura and Nicolas Roche and Roberto Rodr{\'i}guez-Rois{\'i}n and Don D. Sin and Dave Singh and Robert A Stockley and J{\o}rgen Vestbo and Jadwiga A Wedzicha and Alvar Agust{\'i}},
  journal={Respirology},
  year={2017},
  volume={22},
  pages={575 - 601}
}
This Executive Summary of the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 Report focuses primarily on the revised and novel parts of the document. The most significant changes include: (i) the assessment of chronic obstructive pulmonary disease has been refined to separate the spirometric assessment from symptom evaluation. ABCD groups are now proposed to be derived exclusively from patient symptoms and… 
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019
TLDR
Blood eosinophils are recommended as a biomarker to support clinical decisions regarding the use of inhaled corticosteroids in chronic obstructive pulmonary disease patients, based on recent evidence from clinical trials.
COPD Guidelines: A Review of the 2018 GOLD Report
TLDR
The salient features of the GOLD 2018 document are reviewed and commentary on features that merit further discussion are provided based on clinical experience and practice as well as literature review current as of February 2018.
The Importance of Appropriate Diagnosis in the Practical Management of Chronic Obstructive Pulmonary Disease
TLDR
An understanding is provided of the importance of an appropriate diagnosis in the real-world management of COPD and the need to provide appropriate management based on COPD guidelines.
Outcome of Regular Inhaled Treatment in GOLD A Chronic Obstructive Pulmonary Disease Patients
TLDR
Regular inhaled treatment in group A patients with COPD was associated with a symptomatic benefit but not with a reduction of exacerbation rates.
Defining severe obstructive lung disease in the biologic era: an endotype-based approach
TLDR
The definition of severe obstructive lung disease must be updated so that it includes all patients who could benefit from novel treatments and for whom associated costs are justified, allowing targeted biologic therapies to benefit a greater proportion and range of patients.
Differential Features of COPD in China
TLDR
The clinical characteristics of COPD in China, as well as current concepts for COPD diagnosis and treatment, and future actions to improve disease management in the country are summarized.
Pulmonologists Adherence to the Chronic Obstructive Pulmonary Disease GOLD Guidelines: A Goal to Improve
TLDR
Pulmonologist adherence to the GOLD guidelines is not optimal and needs to be improved, and among the factors that influence the inappropriateness of COPD treatments, cardiovascular comorbidities and low-risk Groups A and B are important.
Effects of a comprehensive, inpatient pulmonary rehabilitation programme in a cachectic patient with very severe COPD and chronic respiratory failure
TLDR
An increasing number of specific (non-pharmacological interventions are available and can be combined with PR in the subgroup of patients with very advanced disease, including neuromuscular electrical stimulation (NMES), noninvasive ventilatory support and anabolic agents.
Precision medicine in COPD: where are we and where do we need to go?
TLDR
It is possible that multiOMICs can be used as a tool to integrate data from multiple fields and analysis of electronic medical records could aid in the treatment of patients and in the predictions of outcomes.
Adequacy and prognostic impact of treatment for severe exacerbation of chronic obstructive pulmonary disease
TLDR
Overall compliance with the clinical guidelines for drug treatment was low, and only appropriate use of systemic steroids was associated with a reduction in early mortality and in medium-term readmissions.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 396 REFERENCES
GOLD 2011 disease severity classification in COPDGene: a prospective cohort study.
TLDR
Significant heterogeneity in prospective exacerbation rates (exacerbations/ person-years) were seen, especially in the D subcategories, depending on the risk factor that determined category assignment and the choice of symptom measure influences category assignment.
Integrated disease management interventions for patients with chronic obstructive pulmonary disease.
TLDR
Compared with controls, IDM showed a statistically and clinically significant improvement in disease-specific QoL on all domains of the Chronic Respiratory Questionnaire after 12 months and quality of evidence was scored as high quality, and on the CRQ as moderate quality evidence.
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper
TLDR
The main goals of the updated document are to improve the quality of care provided to patients with COPD and to develop the project using a disease-oriented approach.
Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index.
TLDR
The DOSE Index is a simple, valid tool for assessing the severity of COPD, related to a range of clinically important outcomes such as health care consumption and predicts future events.
COPD exacerbations: defining their cause and prevention
TLDR
The future of exacerbation prevention is in assessment of optimum combinations of pharmacological and non-pharmacological therapies that will result in improvement of health status, and reduction of hospital admission and mortality associated with COPD.
Inhaled corticosteroids for stable chronic obstructive pulmonary disease.
TLDR
Patients and clinicians should balance the potential benefits of inhaled steroids in COPD (reduced rate of exacerbations, reduced rate of decline in quality of life), against the known increase in local side effects (oropharyngeal candidiasis and hoarseness).
Susceptibility to exacerbation in chronic obstructive pulmonary disease.
TLDR
Although exacerbations become more frequent and more severe as COPD progresses, the rate at which they occur appears to reflect an independent susceptibility phenotype, which has implications for the targeting of exacerbation-prevention strategies across the spectrum of disease severity.
Mortality in COPD: role of comorbidities
TLDR
The current paper reviews the role of comorbidities in chronic obstructive pulmonary disease mortality, the putative underlying pathogenic link between chronic obstructives pulmonary disease and comorbrid conditions (i.e. inflammation), and the tools used to predict Chronic obstructivemonary disease mortality.
Complex chronic comorbidities of COPD
TLDR
The current authors believe that lung function measurement, noninvasive assessment of cardiovascular and metabolic functions, and circulating inflammatory markers (e.g. C-reactive protein) might help to better characterise patients with COPD.
Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data.
TLDR
Neither GOLD COPD classification schemes have sufficient discriminatory power to be used clinically for risk classification at the individual level to predict total mortality for 3 years of follow-up and onwards, and the prognostic accuracy of the staging documents for mortality is compared.
...
1
2
3
4
5
...